Stocks
Ascendis Pharma A/SASND
NASDAQHealthcareBiotechnology$225.98-1.32%
Focused on developing innovative endocrine rare disease therapies, this biopharmaceutical company has gained investor attention for its TransCon technology platform. Its lead product, Skytrofa for pediatric growth hormone deficiency, represents a potential blockbuster in a niche market with limited competition.
Market Cap: $13.9B52W Range: $124.06 – $248.60
Congressional Interest in Ascendis Pharma A/S (ASND)
1 member of Congress has disclosed 3 trades in Ascendis Pharma A/S (ASND), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
1
Buys
2
Sells
1
Who in Congress Is Trading ASND?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-10-05 | Gary Palmer | sell | $1K – $15K |
| 2018-08-06 | Gary Palmer | buy | $1K – $15K |